CelestiaSavoyeHiganoMD

Oncology • Seattle, WA

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine University of Washington, Fred Hutchinson Cancer Research Center

Join to view full profile

Dr. Higano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Higano's full profile

Already have an account?

Office
3515 E Spring St
Seattle, WA 98122
Phone+1 206-972-7952

Fax+1 206-329-7316

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1979 - 1982
University of Massachusetts Medical SchoolClass of 1979
University of WashingtonFellowship, Medical Oncology

Certifications & Licensure

CA State Medical License 2010 - 2026
WA State Medical License 1982 - 2026
MN State Medical License 1980 - 1985
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013

Clinical Trials

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer Start of enrollment: 1999 Jan 05
Completed
Phase 3
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer Start of enrollment: 1997 Jan 08
Completed
Phase 2
Study of Aranesp to Treat Anemia in Prostate Cancer Patients. Start of enrollment: 2003 Apr 01
Completed
Phase 2
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer Start of enrollment: 2002 Mar 12
Completed
Phase 2
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 1, Phase 2
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer Start of enrollment: 2005 Feb 01
Terminated
Phase 2
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2013 May 01
Withdrawn
Phase 1
Cabozantinib in Men With Castration-Resistant Prostate Cancer Start of enrollment: 2013 Jun 18
Terminated
Phase 2
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Jan 23
Completed
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma Start of enrollment: 2019 Oct 08
Terminated
Join now to see all

Publications & Presentations

PubMed

Editorial Comment.
Celestia S Higano, Heather Cheng
The Journal of Urology. 2024-12-01
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Confere...
Alan H Bryce, Neeraj Agarwal, Himisha Beltran, Maha H Hussain, Oliver Sartor
Cancer. 2024-12-01
2 citations
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.
Darryl P Leong, Vincent Fradet, Tamim Niazi, Joseph B Selvanayagam, Robert Sabbagh
JACC. Cardiooncology. 2024-10-01

Journal Articles

Development and Validation of a Prognostic Model for Overall Survival in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
G Sonpavde, C S Higano, T M Beer, Annals of Oncology

Lectures

Genitourinary (Prostate) Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Prostate Cancer: What's New in Diagnosis and Treatment?
2019 ACP Internal Medicine Meeting, Philadelphia - 4/11/2019
Balancing Toxicities, and Therapeutics Perspective
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Oral ADT Slashes Heart Risk in Advanced Prostate CancerMay 30th, 2020
New Drugs Make Headway Against Lung, Prostate, Colon CancersMay 29th, 2020
Provenge Extends Survival of mCRPC Patients by up to 4 Years, Data ShowSeptember 9th, 2019
Join now to see all